SARC048 October 7, 2026 Comparing treatment with versus without neoadjuvant DOXOrubicin and ifosfamide in selected patients with high-risk resectable soft-tissue sarcoma TYPE OF SARCOMA: high-grade UPS or LPS of the extremities or trunk wall, with tumor size ≥5 cmDRUG: DOXOrubicin, Ifosfamide, Pembrolizumab ACCRUAL STATUS: Not recruiting patients OVERALL STUDY PRINCIPAL INVESTIGATOR: David Liebner, MD, Ohio State University Comprehensive Cancer Center CLINICALTRIALS.GOV IDENTIFIER: NCT07823491FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICAL TRIALS To contact the study research staff: Contact SARC